Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rene Choi (NPI 1881038404)

Field	Value
Entity Type	Individual
Organization	Rene Choi
Address	3375 Sw Terwilliger Blvd
City	Portland
State	OR
ZIP	97239
Taxonomy	Ophthalmology Physician
NPI Enumerated	April 25, 2013

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider’s billings are effectively single–payer: total Medicare revenue is $2.2M while there is no Medicaid billing on file, indicating the practice derives its publicly reported revenue entirely from Medicare and has no recorded Medicaid activity. That payer mix suggests exposure concentrated to Medicare reimbursement policy and beneficiary demand rather than state Medicaid contract dynamics.

Revenue is highly concentrated in a small set of ophthalmologic drug codes: the precomputed top 3 Medicare codes (J0178, J2777, Q5128) account for 75.9% of this provider’s total Medicare revenue, with individual shares of 47.8%, 23.1%, and 5.1% respectively. This concentration implies the practice’s financial performance is driven largely by intravitreal pharmacologic therapy rather than broad ambulatory E/M alone.

The code mix and descriptions point to a retina-focused ophthalmology practice that performs recurrent intravitreal injections and associated diagnostics: high-revenue drug codes J0178 (aflibercept), J2777 (faricimab), and Q5128 (ranibizumab biosimilar) dominate claims; procedural codes such as 67028 (intravitreal injection) and implants like J7312 (dexamethasone intravitreal implant) appear as material contributors, and retinal imaging 92134 is also billed frequently. Together these codes are consistent with a practice delivering office-based retinal injection therapy plus imaging follow-up.

On competitive standing for major drug codes the provider appears to be a modest, typical national participant: J0178 is responsible for $1.1M in revenue (47.8% of Medicare revenue) and ranks #795 of 3204 providers (75th percentile; typical, unremarkable volume), while J2777 generates $508.1K (23.1%) and ranks #613 of 2039 (70th percentile; typical, unremarkable volume). Q5128 contributes $111.6K (5.1%) and ranks #226 of 373 (40th percentile; typical, unremarkable volume), so the practice does not appear to be a dominant national outlier for its highest-revenue drugs.

Certain non-drug service lines show above-typical national volume: retinal imaging 92134 has 1.9K claims for $57.8K and ranks #1104 of 26868 providers (96th percentile; notably above typical national volume), and new-patient E/M codes 99204 and 99205 are also elevated (154 claims/$18.8K at #9941 of 227068, 96th percentile; and 89 claims/$14.3K at #4228 of 66257, 93th percentile, both noted as notably above typical). These higher percentiles suggest relatively heavy use of diagnostic imaging and higher-complexity new-patient evaluations compared with peers.

There are other notable procedure-level standings: intravitreal dexamethasone implant J7312 accounts for $77.6K (3.5% of Medicare revenue) with 521 claims and ranks #38 of 492 providers (92th percentile) but is described in the data as typical, unremarkable volume; similarly, the intravitreal injection procedure 67028 has 1.1K claims for $103.1K and ranks #1273 of 4255 (70th percentile; typical, unremarkable volume). These entries reinforce that therapeutic intravitreal procedures and implants are routine components of the practice’s mix.

The absence of any Medicaid billing means the provider’s public payer footprint is concentrated in the Medicare market and may reflect patient demographics (Medicare-age patients) or payer credentialing choices; analysts seeking Medicaid exposure or dual-eligible activity should note there is no Medicaid activity on file to analyze. For payers and contracting teams, this profile signals negotiation and quality metrics should be assessed primarily against Medicare-focused retinal/injection practices.

The provider’s NPI enumeration date is 2013-04-25 (~13 years ago), indicating an established presence in the market; combined with the high counts for injections and retinal imaging, this tenure supports characterization as an experienced ophthalmology/retina clinician with an established injection-based service line rather than a newly entered practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

15 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,540	$690	$1.1M
J2777	Injection, faricimab‑svoa, 0.1 mg	17,520	$30	$508.1K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	510	$220	$111.6K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,100	$90	$103.1K
J3490	Unclassified drugs	40	$1,890	$81.1K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	520	$150	$77.6K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,930	$30	$57.8K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	590	$90	$52.9K
J2778	Injection, ranibizumab, 0.1 mg	280	$180	$50.7K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	640	$60	$39.2K

Showing 1–10 of 15

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

Rene Choi — 6 of 15 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

15 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	13	60	840	$680	$623.7K
J2777	8	30	10,050	$30	$527.6K
J2778	16	20	400	$180	$87.8K
67028	24	70	580	$90	$72.3K
Q5128	1	10	290	$220	$63.1K
J7312	1	10	300	$150	$47.7K
J3490	23	50	40	$640	$42.9K
67108	5	10	20	$1,030	$25.7K
92014	25	440	110	$80	$16K
92235	7	30	60	$100	$11.1K

Showing 1–10 of 15

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rene Choi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Professional Services	OR	General Practice Physician	$0	$55.6M
Legacy Clinics LLC	OR	Clinic/Center	$35.6K	$48.7M
University Professional Services	OR	Pharmacy	$0	$8.1M
Ashkan Abbey	TX	Ophthalmology Physician	$6.4M	$0
Lori Coors	TX	Ophthalmology Physician	$5.2M	$0
Ivan Castillo-salazar	TX	Ophthalmology Physician	$4.7M	$0
Andrew Mcclellan	TX	Ophthalmology Physician	$4.5M	$0
Wayne Solley	TX	Ophthalmology Physician	$4M	$0
Christopher Fuller	TX	Ophthalmology Physician	$3.6M	$0
Timothy Fuller	TX	Ophthalmology Physician	$3.5M	$0

Nearby Providers

Other providers in the same ZIP code as Rene Choi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oregon Health & Science University	OR	General Acute Care Hospital	$0	$70.6M
Oregon Health & Science University	OR	Clinic/Center	$0	$52.1M
Shriners Hospitals For Children	OR	Children's Hospital	$0	$3.9M
Portland Dbt Institute, Inc.	OR	Cognitive & Behavioral Psychologist	$0	$3.7M
Housecall Providers, PC	OR	Family Medicine Physician	$0	$2M
Pediatric Orthotic And Prosthetic Services - Northwest, LLC	OR	Prosthetic/Orthotic Supplier	$0	$1.2M
Steven Bailey	OR	Retina Specialist (Ophthalmology) Physician	$1M	$0
Housecall Providers Services, LLC	OR	Community Based Hospice Care Agency	$0	$953.5K
Mind Solutions LLC	OR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$952.2K
John Campbell	OR	Retina Specialist (Ophthalmology) Physician	$885.9K	$0

Rene Choi — Billing Profile & Reimbursement Data

Sign up for Rene Choi — Billing Profile & Reimbursement Data policy alerts

Rene Choi — Billing Profile & Reimbursement Data

Sign up for Rene Choi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References